Form 4: Harvard Bioscience Director Loy Bertrand Reports Acquisition of Restricted Stock Units

Director Bertrand Loy reports acquiring 56,575 restricted stock units in Harvard Bioscience, Inc.

Summary

• On May 21, 2024, Bertrand Loy, a director of Harvard Bioscience, Inc. (HBIO), acquired 56,575 shares of common stock in the form of restricted stock units.
• The restricted stock units were awarded at a price of $0.00.
• These units vest fully on the earlier of the next Annual Meeting of Stockholders after May 14, 2024, or May 21, 2025.
• Following the transaction, Loy directly owns 56,575 shares and indirectly owns 499,633 shares through the Bertrand M. Loy Revocable Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing a common transaction. The acquisition of stock units by a director is generally viewed as a slightly positive sign, but the document itself is purely informational.

Positives

• The acquisition of restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions and provides insight into the compensation structure and ownership stake of a key company director.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's increased stake in the company.

Key Dates